Alnylam outlines ambitions, pipeline progress at R&D day

In its R&D day presentation Friday, Alnylam outlined its goals of becoming a self-sustaining company with at least eight approved drugs and 10 late-stage clinical candidates by 2025, with safer GalNAc conjugates, a late-stage amyloidosis program and a new candidate for Huntington disease as part of the plan.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said it expects to exceed expectations from its R&D plan announced in 2015. That plan, Alnylam 2020, called for three marketed products and 10 therapeutics in the clinic by next year; the company now believes it can have four approved drugs and 14 clinical programs, including six in late-stage testing, by YE20...